In the present study, the DC function and Th17/Treg balance are impaired during the progression of lung cancer, and Pir-B is involving in inhibiting the DC function and Th17 response and promoting Treg differentiation via IL-6 pathway. The gene discussed is IL6; the disease is lung carcinoma.